Chan Henry Lee Sells 1,660 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 1,660 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $349.52, for a total value of $580,203.20. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, January 7th, Chan Henry Lee sold 664 shares of BeOne Medicines stock. The shares were sold at an average price of $331.76, for a total transaction of $220,288.64.
• On Thursday, December 11th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $325.00, for a total transaction of $107,900.00.
• On Wednesday, November 12th, Chan Henry Lee sold 996 shares of BeOne Medicines stock. The stock was sold at an average price of $349.17, for a total transaction of $347,773.32.

BeOne Medicines Trading Up 2.0%

Shares of ONC traded up $6.92 during trading hours on Friday, hitting $353.92. 269,697 shares of the stock were exchanged, compared to its average volume of 307,691. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $196.45 and a fifty-two week high of $385.22. The business has a 50-day moving average of $327.67 and a 200-day moving average of $324.50. The firm has a market capitalization of $38.81 billion, a P/E ratio of 693.96 and a beta of 0.52. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.39 and a quick ratio of 2.17.

Hedge Funds Weigh In On BeOne Medicines

A number of large investors have recently modified their holdings of the company. Legal & General Group Plc purchased a new stake in shares of BeOne Medicines in the second quarter worth approximately $13,857,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in BeOne Medicines by 1,019.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 42,816 shares of the company’s stock worth $14,587,000 after buying an additional 38,992 shares in the last quarter. Virtus Investment Advisers LLC bought a new position in BeOne Medicines during the 2nd quarter valued at $389,000. Baird Financial Group Inc. bought a new position in BeOne Medicines during the 2nd quarter valued at $82,895,000. Finally, Fox Run Management L.L.C. purchased a new position in BeOne Medicines during the 2nd quarter worth $496,000. 48.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ONC has been the topic of a number of recent analyst reports. Zacks Research downgraded BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 28th. Barclays boosted their price target on BeOne Medicines from $385.00 to $394.00 and gave the company an “overweight” rating in a research note on Wednesday. Jefferies Financial Group reaffirmed a “buy” rating and set a $420.00 price objective on shares of BeOne Medicines in a research report on Monday, November 17th. Royal Bank Of Canada reiterated an “outperform” rating on shares of BeOne Medicines in a research note on Wednesday, December 17th. Finally, Sanford C. Bernstein raised shares of BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 target price on the stock in a research note on Monday, January 12th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, BeOne Medicines currently has a consensus rating of “Moderate Buy” and a consensus price target of $379.07.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.